QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://13f.info/13f/000090514824001390-scion-asset-management-llc-q1-2024 

 cantor-fitzgerald-maintains-overweight-on-cigna-group-raises-price-target-to-400

Cantor Fitzgerald analyst Sarah James maintains Cigna Group (NYSE:CI) with a Overweight and raises the price target from $38...

 oppenheimer-maintains-outperform-on-cigna-group-raises-price-target-to-400

Oppenheimer analyst Michael Wiederhorn maintains Cigna Group (NYSE:CI) with a Outperform and raises the price target from $3...

 wall-street-inches-up-after-powells-inflation-remarks-chipmakers-rebound-gold-crude-falter-whats-driving-markets-thursday

U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.

 cigna-crushes-q1-estimates-revenue-soars-with-evernorths-explosive-growth

Cigna beats sales expectations with a 23% Y/Y increase to $57.26 billion, driven by Evernorth Health Services' growth and s...

 cigna-group-q1-2024-adj-eps-647-beats-637-estimate-sales-57255b-beat-55471b-estimate

Cigna Group (NYSE:CI) reported quarterly earnings of $6.47 per share which beat the analyst consensus estimate of $6.37 by 1.57...

 arthritis-patients---cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average ...

 cantor-fitzgerald-reiterates-overweight-on-cigna-group-maintains-384-price-target

Cantor Fitzgerald analyst Sarah James reiterates Cigna Group (NYSE:CI) with a Overweight and maintains $384 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION